Soleus Capital Management’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Soleus Capital Management’s Portfolio TCRR Stock Details TCRR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-47,537	Closed	-$780K	–	87
2021 Q2	$780K	Sell	47,537 -94,600	-67%	-$1.91M	0.12%	61
2021 Q1	$3.14M	Sell	142,137 -57,730	-29%	-$1.57M	0.57%	40
2020 Q4	$6.18M	Sell	199,867 -82,174	-29%	-$2.08M	0.82%	16
2020 Q3	$5.73M	Buy	+282,041	New	+$4.95M	3.04%	13
2020 Q2	–	Sell	-30,624	Closed	-$237K	–	74
2020 Q1	$237K	Buy	+30,624	New	+$375K	0.28%	40

Other funds holding TCRR

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Soleus Capital Management's TCRR Position: Q3 2021 in Review

Soleus Capital Management sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q3 2021, closing a stake of 47,537 shares — an estimated $780K sold.

Soleus Capital Management first reported a position in TCRR in Q1 2020 and held it in 5 quarters. The position peaked at $6.18M in Q4 2020. 117 funds tracked by Wall St. Rank hold TCRR as of Q3 2021.

Soleus Capital Management reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Soleus Capital Management sold 47,537 TCR2 Therapeutics Inc. Common Stock shares in Q3 2021, an estimated $780K.
Soleus Capital Management first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2020 and held it in 5 quarters.
Soleus Capital Management's TCR2 Therapeutics Inc. Common Stock position peaked at $6.18M in Q4 2020.
117 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q3 2021.

Based on Soleus Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.